CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME (NCT07449923)

🧪 Interventions in This Study

• EYP-1901 (DRUG)
• Aflibercept (2.0 mg) (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (70 Sites)

Showing the first 25 of 70 sites.

• Associated Retina Consultans — Gilbert, Arizona
• Associated Retina Consultants - Phoenix — Phoenix, Arizona
• Phoenix Retina Clinical Trials, LLC - North Phoenix — Phoenix, Arizona
• Retina Macula Institute of Arizona — Scottsdale, Arizona
• Retina Vitreous Associates Medical Group — Beverly Hills, California
• Retina Consultants of Orange County — Fullerton, California
• South Coast Retina Center — Long Beach, California
• Retinal Consultants Medical Group - Modesto — Modesto, California
• Kaiser Permanente — Oakland, California
• Retina Consultants of Southern California — Redlands, California
• Bay Area Retina Associates — Walnut Creek, California
• Retina Specialists of Colorado - Arvada — Arvada, Colorado
• Connecticut Eye Consultants, P.C. — Danbury, Connecticut
• Coastal Eye Surgeons, LLC — Greenwich, Connecticut
• Retina Group of New England, PC — Waterford, Connecticut
• Retina Group of Florida - Fort Lauderdale — Fort Lauderdale, Florida
• Retina Specialty Institute — Pensacola, Florida
• Fort Lauderdale Eye Institute — Plantation, Florida
• MedEye Associates — South Miami, Florida
• Retina Vitreous Associates of Florida - Saint Petersburg — St. Petersburg, Florida
• Retina Vitreous Associates of Florida — Tampa, Florida
• Retina Associates — Elmhurst, Illinois
• University Retina and Macula Associates — Lemont, Illinois
• Illinois Retina Associates, S.C. — Oak Park, Illinois
• Associated Vitreoretinal & Uveitis Consultants - Carmel — Carmel, Indiana

📞 Contact the Study Coordinator

Phone: (833) 393-7646

Email: rribeiro@eyepoint.bio

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Diabetic Macular Edema

• Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT) — Beverly Hills, California
• 4D-150 in Patients With Diabetic Macular Edema — Hagerstown, Maryland
• Mean Visual Acuity Changes Following Five Injections of Aflibercept — Hamilton, Ontario
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME) — Mesa, Arizona
• A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema — Phoenix, Arizona
• A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME — Mesa, Arizona

Explore by condition: All Diabetic Macular Edema clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.